Northwest Biotherapeutics Company Description

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer.

The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.

Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.

The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers.

Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Northwest Biotherapeutics, Inc.

Country	United States
Founded	1996
Industry	Biological Products, Except Diagnostic Substances
Employees	25
CEO	Linda Powers

Contact Details

Address: 4800 Montgomery Lane Bethesda, Delaware 20814 United States
Phone	240 497 9024
Website	nwbio.com

Stock Details

Ticker Symbol	NBYB
Exchange	Stuttgart Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Linda Powers	Chief Executive Officer
Linda Powers	Chief Financial Officer
David Innes	Head of Investor Relations